This article is more than 5 years old. Information may no longer be current.
VIDEO: Emerging percutaneous therapies improve outcomes in HF, cardiogenic shock
Click Here to Manage Email Alerts
ORLANDO, Fla. — Randall Starling, MD, MPH, director of heart failure at the Cleveland Clinic Foundation, outlines new frontiers in tackling the “devastating problem” of cardiogenic shock after a session dedicated to the topic at the annual AHA Scientific Sessions.
“In this era of urgent revascularization for [MI], we’re saving lives, but a lot of these patients still have cardiogenic shock,” he said.
Calling current pharmacologic options “Band-Aid” solutions, Starling highlights the “exploding area” of percutaneous therapies for acute HF and circulatory shock.
“It’s a marriage of interventional cardiology, HF cardiology, cardiac surgery and intensivists — all working as a team to take care of these patients,” he said.
Starling touches on the promise of left ventricular assist devices, providing context with recent data from the ROADMAP study in patients with HF not dependent on inotropic support.
“We’re seeing that patients are living very well, doing great with survival and patients reported outcomes are showing improved quality of life.”